Floatz logo

Inno-206

Chronic Kidney Disease

Oxford University Hospitals NHS TrustPhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
81/ 100

Competitive context

11 Active assets in the Chronic Kidney Disease cohort.

Asset / SponsorPhaseRating
Semaglutide
Institute of Liver and Biliary Sciences, India
Phase 4BBB
Plavix
Hospital Alemão Oswaldo Cruz
Phase 4BB
Acetylsalicylic Acid
Hospital Alemão Oswaldo Cruz
Phase 4BB
Rocuronium
Stony Brook University
Phase 4BB
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Kyunghee University Medical Center
Phase 4BB

View all 31 →

Same molecule, other indications

Inno-206 is also rated in:

adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
plasma cell myelomaDormant
BBB
Indicative ·
77 / 100
View asset →
Recurrent Adult Acute Lymphoblastic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →